Literature DB >> 17295241

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Thomas Hocker1, Hensin Tsao.   

Abstract

Despite the large body of mutational data available for melanoma and epidemiological studies linking this cancer to ultraviolet radiation (UVR), the fundamental carcinogenic mechanisms involved in melanoma remain largely unknown. To this end, we systematically reviewed, extracted, and analyzed mutational data from the extant melanoma literature in an effort to gain more insight into its early pathogenic events. We searched PubMed (1966-January 2006) using the words "mutation" AND "melanoma" in the title or abstract. Out of 2,095 returned results, there were 203 eligible studies that were subsequently analyzed. We cataloged 8,201 somatic and cultured melanoma specimens and annotated 2,041 reported somatic sequence variants. The single BRAF c.1799T>A (p.Val600Glu) alteration is the most prevalent variant while other A:T>T:A transversions were uncommon. Four highly-recurrent, non-ultraviolet B (UVB) changes account for most of the NRAS and BRAF variants. CDKN2A, PTEN/MMAC1, and TP53 harbored statistically higher rates of UVB signature changes (64.2%, 52.4%, and 69.2%, respectively) than oncogenic loci (NRAS: 15.3% and BRAF: 2.4%). More specifically, cutaneous melanomas showed a significantly higher proportion of UVB signature mutations at both TP53 and CDKN2A when compared to non-skin cancers using data from their respective locus-specific databases. Superficial spreading and nodular melanomas had the highest rates of BRAF (53.4%) and NRAS (28.0%) mutations. In melanoma, there is sufficient mutational evidence to support a role for direct UVB participation, especially at TP53 and CDKN2A. For oncogenes, the role for UVB is less clear since functionally-activating changes are uncommon and are subject to sequence constraints.

Entities:  

Mesh:

Year:  2007        PMID: 17295241     DOI: 10.1002/humu.20481

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  87 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 4.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 5.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

6.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.

Authors:  Heidi V N Küsters-Vandevelde; Jan E E Keunen; Pieter Wesseling; Marian A J Verdijk; Marjolijn J L Ligtenberg; Willeke A M Blokx
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

8.  Genome-wide analysis of DNA methylation in UVB- and DMBA/TPA-induced mouse skin cancer models.

Authors:  Anne Yuqing Yang; Jong Hun Lee; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Yaoping Lu; Mou-Tuan Huang; Christina Ramirez; Douglas Pung; Ying Huang; Michael Verzi; Ronald P Hart; Ah-Ng Tony Kong
Journal:  Life Sci       Date:  2014-08-02       Impact factor: 5.037

9.  Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Authors:  Molly K Altman; Vashisht Gopal; Wei Jia; Shuangxing Yu; Hassan Hall; Gordon B Mills; A Cary McGinnis; Michael G Bartlett; Guowei Jiang; Damian Madan; Glenn D Prestwich; Yong Xu; Michael A Davies; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-06-09       Impact factor: 27.401

10.  The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

Authors:  Abel D Jarell; Donald Lawrence; Hensin Tsao
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.